Cameron Turtle, CEO of Spyre Therapeutics,Inc. speaks with Venrock partner Nimish Shah about Spyre’s priorities for 2025, building a collaborative and productive Board, how culture shines through when the going gets tough, and the best advice he's ever received.

This podcast was recorded in December 2024. Please be advised that comments made during this podcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Spyre Therapeutic, Inc.'s (“Spyre”) expectations regarding Spyre’s product candidates including their potential safety and efficacy, business and clinical trial plans, milestones and timelines. All statements other than statements of historical fact are forward-looking statements and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. For further details concerning these risks and uncertainties, please refer to Spyre's SEC filings, including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q. These forward-looking statements are only as of the date they were made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements.